10 lessons for using social media from a former FDA official

03/27/2013 | PharmaLive.com

Pharma companies are wary about how they communicate with patients through social media, but the FDA's 2011 draft guidance, "Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices," offers some valuable insight, writes Peter Pitts, president of the Center for Medicine in the Public Interest and a former associate commissioner at the FDA. Pitts advises companies to remember that the message is what is important to the FDA, not the medium, and he offers 10 insights into the agency's draft guidance.

View Full Article in:

PharmaLive.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD